Objective To analyze the expressions of microRNA-221(miR-221)and microRNA-630(miR-630)in patients with non-small cell lung cancer(NSCLC)and their relationship with the prognosis.Methods Cancer tissue and adjacent tissue samples from 198 patients with NSCLC were collected.The expressions of miR-221 and miR-630 were detected.The relationship with pathological characteristics was analyzed.Kaplan-Meier method was used to analyze 2-year survival.Cox regression analysis was conducted to investigate the relationship between the expressions of miR-221 and miR-630 and the prognosis.Results The expressions of miR-221 in cancer tissues was higher than that in adjacent tissues,and the expressions of miR-630 was lower than that in adjacent tissues(P＜0.05).The expression of miR-221 in tumor tissue of NSCLC patients at TNM stage Ⅲ-Ⅳ with lymph node metastasis was higher than that in patients at TNM stage Ⅰ-Ⅱ and without lymph node metastasis(P＜0.05).The expression of miR-630 in tumor tissues of NSCLC patients at TNM stage Ⅲ-Ⅳ with tumor diameter ≥ 4 cm and with lymph node metastasis was lower than that in patients at TNM stage Ⅰ-Ⅱ with tumor diameter＜4 cm and without lymph node metastasis(P＜0.05).Kaplan-Meier analysis showed that the 2-year survival rate of those with high expression of miR-221 was 55.56％that was lower than 79.63％of those with low expression of miR-221.The 2-year survival rate of those with high expression of miR-630 was 75.96％that was higher than 50.00％of those with low expression of miR-630(P＜0.05).Cox regression analysis showed that TNM stage,lymph node metastasis,and expressions of miR-221 and miR-630 were prognostic factors of NSCLC(P＜0.05).Spearman correlation analysis showed that the expression of miR-221 was negatively correlated with that of miR-630(P＜0.05).Conclusions The expression of miR-221 is increased and expression of miR-630 is decreased in patients with NSCLC.Their expressions are related to TNM staging,lymph node metastasis,and the prognosis.The two can be used as potential prognostic markers in patients with NSCLC.
维普
万方数据